Omega Healthcare Investors (OHI) Q1 2025 earnings summary

Executive summary

• Q1 2025 net income was $112.1 million ($0.33/share), up from $69.3 million ($0.27/share) in Q1 2024, driven by higher rental and interest income, facility acquisitions, and improved operator performance.

• Adjusted FFO for Q1 2025 was $221 million ($0.75/share), and FAD was $211 million ($0.71/share), both up year-over-year, reflecting revenue and EBITDA growth, primarily funded with equity, reducing leverage to 3.7x debt to EBITDA.

• 2025 AFFO guidance was raised and narrowed to $2.95–$3.01 per share, reflecting strong Q1 earnings, new investments, and the dilutive impact of share issuances.

• Genesis missed March rent but paid in April; Omega's credit position with Genesis remains strong, with over 1.6x rent coverage and fully secured term loan.

• Revenue mix has shifted significantly, with private pay and other revenue rising from 8% to 39% over the past decade.

Financial highlights

• Q1 2025 revenue was $277 million, up from $243 million in Q1 2024, driven by new investments, operator restructurings, and annual escalators, partially offset by asset sales.

• NAREIT FFO for Q1 2025 was $184 million ($0.62/share), compared to $153 million ($0.60/share) in Q1 2024.

• Operating cash flow increased to $182 million from $151.5 million year-over-year.

• Interest expense declined after repaying $400 million in senior notes; $264 million in equity was raised in Q1 to prefund investments.

• Total assets at March 31, 2025 were $9.7 billion; total equity $4.9 billion; total debt $4.5 billion (47.5% of capitalization).

Outlook and guidance

• Full-year 2025 adjusted FFO guidance raised to $2.95–$3.01 per share, reflecting Q1 actuals and $423 million in new investments.

• Guidance assumes stable operator revenue, continued rent payments from Maplewood and Genesis, and no material changes in market interest rates.

• Management expects sources of cash to be adequate for the next 12 months, covering dividends, debt service, investments, and G&A.

• Quarterly G&A expense projected at $12–$14 million for 2025.